Health

SoftBank Vision Fund 2 led the healthcare management software provider’s series D round, taking its overall funding to about $213m and its valuation to a reported $1.4bn.

The company, which largely remains in stealth mode, has set itself a mission of increasing the human lifespan by a decade.

The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

Kaiser Permanente Ventures returned to reinvest in the nursing staff management service at a $1.1bn valuation.

The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.

The Swisscom-backed round was buttressed with an additional $47m to support the virtual experiment provider's expansion plans.

AMR Action Fund added $20m to a round for the drug-resistant bacteria treatment developer following a Mayo Clinic-backed first close last May.

The China Resources and Legend Holdings-backed vaccine technology developer floated in Hong Kong in a $97.7m offering following nearly $460m in funding.

Sector report: oncology

Oncology Q1 2022 editorial by James Mawson, editor in chief, Global Corporate Venturing

PTT Oil and Retail, Central Pattana, The Vacharaphol, TKS Technologies, Ramkhamaeng Hospital, Modernform, MC Group, Singha and Benchachinda are among the fund's limited partners.